

APOLLO HOSPITALS ENTERPRISE LIMITED

CIN : L85110TN1979PLC008035



30th May 2025

The Secretary,
Bombay Stock Exchange Ltd (BSE)
Phiroze Jheejheebhoy Towers,
Dalal Street,
Mumbai – 400 001.
Scrip Code – 508869
ISIN INE437A01024

The Secretary,
National Stock Exchange,
Exchange Plaza, 5th Floor
Plot No.C/1, 'G' Block
Bandra – Kurla Complex
Bandra (E)
Mumbai – 400 051.
Scrip Code–
APOLLOHOSP
ISIN INE437A01024

Dear Sir,

Subject: Disclosure under Regulation 30 the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

In compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the Investor Presentation on the Financial Results of the Company for three and year ended March 31, 2025.

The presentation to be made to the Investors is enclosed and the same is also being uploaded on the Company's website www.apollohospitals.com.

Kindly note of the same.

Thanking You,

Yours faithfully,
For APOLLO HOSPITALS ENTERPRISE LIMITED

S.M. KRISHNAN
Sr. VICE PRESIDENT – FINANCE
AND COMPANY SECRETARY

IS/ISO 9001 : 2000


Regd. Office :
19, Bishop Gardens,
Raja Annamalaipuram,
Chennai - 600 028.

General Office :
"Ali Towers" III Floor,
#55, Greams Road,
Chennai - 600 006.

Tel : 044 - 2829 0956 / 3896 / 6681
Telefax : 044 - 2829 0956
Email : investor.relations@apollohospitals.com
Website : www.apollohospitals.com



Apollo Hospitals Enterprise Limited



Earnings Update Q4 FY25

The information contained in this presentation is provided by Apollo Hospitals Enterprise Limited (the “Company”) to you solely for your reference. This document is being given solely for your information and for your use and may not be retained by you and neither this presentation nor any part thereof may be (i) used or relied upon by any other party or for any other purpose; (ii) copied, photocopied, duplicated or otherwise reproduced in any form or by any means; or (iii) redistributed, passed on or otherwise disseminated, to any other person without the prior written consent of the Company. Although care has been taken to ensure that the information in this presentation is accurate, and that the opinions expressed are fair and reasonable, the information is subject to change without notice, its accuracy is not guaranteed and has not been independently verified. No representation, warranty, guarantee or undertaking (express or implied) is made as to, and no reliance should be placed on, the accuracy, completeness or correctness of any information, including any projections, estimates, targets and opinions, contained herein, and accordingly, none of the Company, its advisors, representatives or any of its directors assumes any responsibility or liability for, the accuracy or completeness of, or any errors or omissions in, any information or opinions contained herein. None of the Company, its advisors, representatives and its directors, officers, employees or affiliates nor any other person accepts any responsibility or liability (whether arising in tort, contract or otherwise) whatsoever for any loss, cost or damage suffered or incurred howsoever arising, directly or indirectly, from any use of this presentation or its contents or otherwise arising in connection therewith, and makes no representation or warranty, express or implied, for the contents of this presentation including its accuracy, fairness, completeness or verification or for any other statement made or purported to be made by any of them, or on behalf of them, and nothing in this presentation or at this presentation shall be relied upon as a promise or representation in this respect, whether as to the past or the future.

The statements contained in this document speak only as at the date as of which they are made, and the Company expressly disclaims any obligation or undertaking to supplement, amend or disseminate any updates or revisions to any statements contained herein to reflect any change in events, conditions or circumstances on which any such statements are based. By preparing this presentation, none of the Company, its management, and their respective advisers undertakes any obligation to provide the recipient with access to any additional information or to update this presentation or any additional information or to correct any inaccuracies in any such information which may become apparent. This document does not constitute or form part of and should not be construed as an offer to sell or issue or the solicitation of an offer to buy or acquire securities of the Company or its subsidiaries or affiliates in any jurisdiction or as an inducement to enter into investment activity. No part of this document, nor the fact of its distribution, should form the basis of, or be relied on in connection with, any contract or commitment or investment decision whatsoever. You acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Company. This document is not financial, legal, tax or other product advice. Any person/ party intending to provide finance/ invest in the Company shall do so after seeking their own professional advice and after carrying out their own due diligence procedure to ensure that they are making an informed decision.

This presentation contains statements that constitute forward-looking statements which involve risks and uncertainties. These statements include descriptions regarding the intent, belief or current expectations of the Company or its officers and information currently available with them including with respect to the consolidated results of operations and financial condition, and future events and plans of the Company. These statements can be recognized by the use of words such as “expects”, “plans”, “will”, “estimates”, “intends” or words of similar meaning. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and actual results may differ from those in the forward-looking statements as a result of various factors and assumptions. Neither the Company nor its affiliates or advisors or representatives guarantees that the assumptions underlying such forward-looking statements are free from errors nor do they accept any responsibility for either the future accuracy of the forward-looking statements contained in this presentation or the actual occurrence of the forecasted developments. You are cautioned not to place undue reliance on these forward looking statements, which are based on the current view of the management of the Company on future events. No assurance can be given that future events will occur, or that assumptions are correct. Neither the Company nor its advisors or representatives assume any responsibility to amend, modify or revise any forward-looking statements, on the basis of any subsequent developments, information or events, or otherwise. Certain numbers in these presentations and materials have been subject to routine rounding off and accordingly figures shown as total in tables and diagrams may not be an arithmetic aggregation of the figures that precede them.


This presentation has not been approved and will not or may not be reviewed or approved by any statutory or regulatory authority in India or by any stock exchange in India. This presentation does not purport to be a complete description of the markets conditions or developments referred to in the material. This presentation includes certain industry data and projections that have been obtained from industry publications and surveys. Industry publications and surveys and forecasts generally state that the information contained therein has been obtained from sources believed to be reliable, but there is no assurance that the information is accurate or complete. Neither the Company nor any of its advisors or representatives have independently verified any of the data from third-party sources or ascertained the underlying economic assumptions relied upon therein. All industry data and projections contained in this presentation are based on data obtained from the sources cited and involve significant elements of subjective judgment and analysis, which may or may not be correct. For the reasons mentioned above, you should not rely in any way on any of the projections contained in this presentation for any purpose.

The distribution of these materials in certain jurisdictions may be restricted by law and persons into whose possession these materials comes should inform themselves about and observe any such restrictions.

This presentation and the information contained herein does not constitute or form part of any offer for sale or subscription of or solicitation or invitation of any offer to buy or subscribe for any securities of the Company, nor should it or any part of it form the basis of, or be relied on in connection with, any contract or commitment whatsoever. This presentation is not a prospectus, a statement in lieu of a prospectus, an offering circular, an advertisement or an offer document under the Companies Act, 2013, and the rules made thereunder, as amended, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended, or any other applicable law in India. This presentation is not an offer of securities for sale in the United States. Securities may not be offered or sold in the United States absent registration or an exemption from registration.

By accessing this presentation, you accept that this disclaimer and any claims arising out of the use of the information from this presentation shall be governed by the laws of India and only the courts in Chennai, India, and no other courts, shall have jurisdiction over the same.

 Financial Performance Snapshot & Business Segment wise Update	4-9
 Consolidated Financials	11-12
 Healthcare Services	14-23
 Diagnostics & Retail Health (AHLL)	25-28
 Digital Health & Pharmacy Distribution (Apollo HealthCo)	30-37
 Annexure	39-40



Financial Performance Snapshot Q4FY25




(in ₹ Mio)		Revenue	Growth YoY(%)	EBITDA(Post Ind AS)	Margin	Growth YoY(%)	PAT	Growth YoY(%)
Healthcare Services		28,219	↑ 10%	6,862	24.3%	↑ 16%	3,851	↑ 37%
Apollo HealthCo	Offline PD ^	20,844	↑ 17%	1,616	7.8%	↑ 21%		
	Online PD^ & 24 7	2,919	↑ 22%	(1,253)	Vs (1,219) in Q4F24			
	Total HealthCo	23,763	↑ 17%	363	1.5%		88	0.4%
AHLL		3,940	↑ 11%	472	12%	↑ 32%	(43)	
Consolidated		55,922	↑ 13%	7,698	13.8%	↑ 20%	3,896	↑ 54%

^PD:- Pharmacy Distribution

Financial Performance Snapshot FY25											
(in ₹ Mio)		Revenue		Growth YoY(%)	EBITDA(Post Ind AS)		Margin	Growth YoY(%)	PAT		Growth YoY(%)
Healthcare Services		111,475		↑ 13%	27,005		24.2%	↑ 15%	14,260		12.8% ↑ 25%
Apollo HealthCo	Offline PD ^		80,143		↑ 16%	6,124		7.6%	↑ 17%		
	Online PD^ & 24 7		10,787		↑ 20%	(4,449)		Vs (6,047) in FY24			
	Total HealthCo		90,930		↑ 16%	1,676		1.8%	469		0.5%
AHLL		15,535		↑ 14%	1,538		9.9%	↑ 32%	(270)		
Consolidated		217,940		↑ 14%	30,219		13.9%	↑ 26%	14,459		6.6% ↑ 61%
^PD:- Pharmacy Distribution											
© 2025 Apollo Hospitals Enterprise Ltd, All Rights Reserved											
5											



Largest Pan India Hospital Chain




	Hospitals	Capacity Census Beds ¹	Operational Census Beds
Overall Total	73	10,187	9,458
Owned Hospitals	45	8,754	8,025
Managed Hospitals	6	790	790
Day Surgery & Cradle (AHLL)	22	643	643

¹Capacity beds include only census capacity beds and doesn't include emergency, daycare beds, recovery room, dialysis, endoscopy etc.

Healthcare Services Q4 FY25 Snapshot





AHLL: Transforming Retail Health through access and convenience



Apollo Health & Lifestyle Ltd



Out-of-Hospital care

- Outpatient Clinics
- Diagnostics
- Day Surgery centers
- Single Specialty Facilities :- Dialysis, Sugar and Dental

Organizing the unorganized

- Pathology – Organized chains represent only ~30%
- Mother and Child, Specialized Surgical Centers
- IVF Centers

AHLL Q4 FY25 Snapshot



Revenue ₹ 3,940 Mio ↑ 11%

EBITDA ₹ 472 Mio ↑ 32%


Margin

12%

Significant **opportunity to grow** the primary care and diagnostics businesses Plays a vital role in last-mile care delivery, and in ensuring continuum of care for the consumer

Offline Pharmacy Distribution

- India's largest **Organized Pharmacy Platform** with presence in ~1,200+ cities/ towns spread across 22 States and 5 union territories.
- **6,626 Operating Stores** as on 31st March 2025.
- **Serving ~ 889,166 customers** 24 x 7 everyday.
- **Private and Generic Label sales at 17.4% (offline) for FY25.**



Apollo 24|7

Unmatched Size

- **40 Mn.+** Registered Users – **820,574** Daily Active Users
- Serving consumers through **network of 6,626 pharmacies**

Industry-leading Growth at scale

- Platform GMV: INR 3,007 Cr. in FY25, growth of 8% over FY24

Full stack digital healthcare platform

- First-in-class AI enabled technologies including India's first Clinical Intelligence Engine

Apollo Telehealth*

- Provides **comprehensive remote healthcare services**.
- Offers **specialized telehealth solutions** like **24/7 Tele-Emergency** and **Tele-Consultancy**.
- Expands access to **healthcare in distant regions**, improving quality of life.
- Operates and maintains Mobile Medical Units/ Mobile Health Units, Patient Facilitation Centres, Digital Dispensaries, and is also engaged in organizing Screening Camps and development of Diagnostic Centres for setting up healthcare awareness programs

*Division of AHEL

Health Co Q4 FY25 Snapshot



~15.5%
Omni Private
label / Generic
sales

Revenue

₹ 23,763 Mio ↑ 17%

EBITDA

₹ 1,966 Mio ↑ 21%
(excl 24|7 operating cost & ESOP)

Margin

8.3%



Virtual Doctor Consultation



Online Booking : Hospitals
& Diagnostics



Online Medicine delivery



Health Insurance



Patient e-health records



Condition management



Hospitals


- **Apollo Hospitals** crossed the milestone of **25,000+ cumulative transplants**, with Hyderabad playing a pivotal role—reaffirming Apollo’s leadership in complex, high-acuity care and transplant innovation.
- **Indraprastha Apollo Hospitals, Delhi** performed a landmark **double lung transplant** on a 42-year-old male patient with end-stage lung disease.
- **Apollo Children’s Hospital, Chennai** successfully performed a left thoroscopic upper lobectomy on a 9-month-old infant with congenital pulmonary airway malformation—**demonstrating advanced pediatric surgical capabilities using minimally invasive techniques.**
- **A strategic Memorandum of Understanding (MoU)** was signed with **Mayapada Healthcare, Indonesia**, to strengthen cross-border medical collaboration and clinical knowledge exchange across Southeast Asia.

AHLL

- Entered into strategic partnership with Eli Lilly for diabetes & weight-loss management drug Mounjaro (tirzepatide). Launched ProHealth Zen program in Apollo One Bangalore. Digital upgrade (Onehub implementation) completed across Primary Care network
- Expansion of test-menu to include Heavy metal testing using ICP-MS, advanced PCR-based assays including CT/NG PCR, TB-PCR for Mycobacterium Tuberculosis (MTB) & Non-Tuberculous Mycobacteria (NTM), HPV Multiplex PCR covering all genotypes, Myeloproliferative Neoplasm (MPN) Panel covering JAK2, CALR, MPL & BCR-ABL mutations, Pharmacogenetic assays for NUDT15 & TPMT, Dried Blood Spot (DBS) analysis for abnormal hemoglobinopathies, Therapeutic Drug Monitoring (Tacrolimus, Sirolimus, Everolimus and Cyclosporine) for immunosuppressants, comprehensive 50-marker Newborn Screening and MALDI-TOF mass spectrometry – 110 tests started inhouse in FY25
- Won PPP Contract for Dialysis in Assam. Partnered with Dabur for Apollo Dental

Apollo HealthCo

- **Enhanced app UI/UX** with improved navigation and cart redesign to increase engagement and conversion.
- **Revamped Ask Apollo** to offer AI enabled health assistance to end users based on their medical history
- Rolling out **ML driven Joint Marketing campaigns** to improve **user conversion for IP /OP in hospitals**
- Integrated third-party SaaS to launch a **self-serve brand portal** to enable better visibility of campaigns & ad spends for partner brands and hence building monetization
- Expanding **customer value proposition** by strengthening Circle's omni channel **offerings, expanding 19 minutes** medicine delivery proposition now from 4 cities to 6 cities & improve the **Same Day Delivery** rates resulting in better conversions
- Launched **full-fledged insurance** product with optimized in-app journeys to boost adoption & growth. Expect to launch products with 12 insurers



Consolidated Financials

Consolidated Financials Q4FY25

₹ Mio		Healthcare Services	Diagnostics & Retail Health	Digital Health & Pharmacy Distribution	Consol
Q4FY25	Total Revenues	28,219	3,940	23,763	55,922
	EBITDA (Pre 24 7 Cost)	6,862	472	1,966	9,301
	margin (%)	24.3%	12.0%	8.3%	16.6%
	24/7 Operating Cost			-1,147	-1,147
	ESOP(Non Cash expense)			-455	-455
	EBITDA	6,862	472	363	7,698
	margin (%)	24.3%	12.0%	1.5%	13.8%
	EBIT	5,239	118	230	5,587
	margin (%)	18.6%	3.0%	1.0%	10.0%
	PBT	5,114	-45	88	5,156
	margin (%)	18.1%	-	0.4%	9.2%
	PAT (Reported)	3,851	-43	88	3,896
Q4FY24	Total Revenues	25,626	3,547	20,267	49,439
	EBITDA (Pre 24 7 Cost)	5,931	357	1,625	7,913
	margin (%)	23.1%	10.1%	8.0%	16.0%
	24/7 Operating Cost			-1,402	-1,402
	ESOP(Non Cash expense)			-106	-106
	EBITDA	5,931	357	117	6,405
	margin (%)	23.1%	10.1%	0.6%	13.0%
	EBIT	4,446	68	-6	4,508
	margin (%)	17.3%	1.9%	-	9.1%
	PBT	3,972	-112	-179	3,682
	margin (%)	15.5%	-	-	7.4%
	PAT (Reported)	2,803	-87	-177	2,538
YOY Growth					
	Revenue	10%	11%	17%	13%
	EBITDA	16%	32%	-	20%
	PAT	37%	-	-	54%

- ✓ Overall Consolidated Revenue grew by 13% to ₹ 55,922 mio.
- ✓ EBITDA grew by 20% to ₹ 7,698 mio.
- ✓ Consolidated PAT grew by 54% to ₹ 3,896 mio.


₹ Mio		Healthcare Services	Diagnostics & Retail Health	Digital Health & Pharmacy Distribution	Consol
FY25	Total Revenues	111,475	15,535	90,930	217,940
	EBITDA (Pre 24 7 Cost)	27,005	1,538	7,533	36,076
	margin (%)	24.2%	9.9%	8.3%	16.6%
	24/7 Operating Cost			-4,781	-4,781
	ESOP(Non Cash expense)			-1,076	-1,076
	EBITDA	27,005	1,538	1,676	30,219
	margin (%)	24.2%	9.9%	1.8%	13.9%
	EBIT	21,217	300	1,127	22,643
	margin (%)	19.0%	1.9%	1.2%	10.4%
	PBT	20,235	-313	469	20,391
	margin (%)	18.2%	-	0.5%	9.4%
	PAT (Reported)	14,260	-270	469	14,459
FY24	Total Revenues	98,670	13,653	78,269	190,592
	EBITDA (Pre 24 7 Cost)	23,558	1,166	6,260	30,984
	margin (%)	23.9%	8.5%	8.0%	16.3%
	24/7 Operating Cost			-6,186	-6,186
	ESOP(Non Cash expense)			-891	-891
	EBITDA	23,558	1,166	-817	23,907
	margin (%)	23.9%	8.5%	-	12.5%
	EBIT	18,361	-15	-1,309	17,037
	margin (%)	18.6%	-	-	8.9%
	PBT	16,431	-670	-1,956	13,805
	margin (%)	16.7%	-	-	7.2%
	PAT (Reported)	11,450	-508	-1,957	8,986
YOY Growth					
Revenue		13%	14%	16%	14%
EBITDA		15%	32%	-	26%
PAT		25%	-	-	61%

- ✓ Overall Consolidated Revenue grew by 14% to ₹ 217,940 mio.
- ✓ EBITDA grew by 26% to ₹ 30,219 mio.
- ✓ PAT grew by 61% to ₹ 14,459 mio.

	HCS	Health Co	AHLL
Gross Debt	21,282	4,345	2,674
Cash & Cash Equivalents*	26,093	795	1,521
Net Debt	-4,812	3,550	1,153

*Includes investments in Liquid funds and FDs of ₹ 22,628 mio.

Consol Gross Debt	28,300
Consol Net Debt	-109



Healthcare Services

Hospitals

₹ Mio	Q4FY25	Q4FY24	YoY	FY25	FY24	YoY
No of Hospitals	45	45		45	45	
Operating beds	8,025	7,945	1%	8,025	7,945	1%
Occupancy	67%	65%		68%	65%	
IP Discharges	146,434	140,572	4%	604,250	564,046	7%
ALOS	3.30	3.33	-1%	3.32	3.33	0%
ARPOB	63,569	59,523	7%	60,588	57,488	5%
Revenue	28,219	25,626	10%	111,475	98,670	13%
EBITDA (Post Ind AS 116)	6,862	5,931	16%	27,005	23,558	15%
margin (%)	24.3%	23.1%	117 bps	24.2%	23.9%	35 bps
EBIT	5,239	4,446	18%	21,217	18,361	16%
margin (%)	18.6%	17.3%	122 bps	19.0%	18.6%	42 bps
PBT	5,114	3,972	29%	20,235	16,431	23%
PAT	3,851	2,803	37%	14,260	11,450	25%
Margin	13.6%	10.9%	271 bps	12.8%	11.6%	119 bps


- ✓ Healthcare Services Revenue grew by 10% in Q4FY25 (Inpatient Volume grew by 4% ; Price & case mix of 6%)
- ✓ Focus on higher growth in CONGO-T specialties (8% YoY volume growth) aided higher revenue realisation in Q4FY25. Volume impact due to reduction in Bangladeshi patient is 1.2% in Q4FY25.
- ✓ Occupancy for Q4FY25 at 67% vs 65% in Q4FY24
- ✓ Average Revenue per In patient grew by 7% to ₹171,358

Capital employed
(ROCE – FY25)



₹ 77,187

ROCE 27.5%


* capital employed excludes CWIP of ₹ 9,210 mio toward new projects under development




Inpatients Revenue Mix FY25



* Oncology includes Radiotherapy and Chemotherapy



Healthcare Services : Operational Snapshot



FY25	Metros	Non Metros
Operating Beds	4,578	3,447
Occupancy	71%	66%
ARPOB [^]	73,593	42,335
ROCE	29%	27%


[^]ARPOB is net of fees paid to fee for service doctors which is netted off in the reported revenues

	Pan India					
	Q4FY25	Q4FY24	YoY	FY25	FY24	YoY
Operating Beds	8,025	7,945	1.0%	8,025	7,945	1.0%
Bed Occupancy Rate (%)	67%	65%		68%	65%	
Inpatient volume	146,434	140,572	4.2%	604,250	564,046	7.1%
Outpatient volume ⁽¹⁾	559,817	479,819	16.7%	2,232,390	1,922,696	16.1%
Inpatient ALOS (days)	3.30	3.33	-1.1%	3.32	3.33	-0.4%
Total Net Revenue (₹ mio) ⁽²⁾	30,788	27,896	10.4%	121,819	108,349	12.4%
Avg revenue per In Patient	171,358	160,076	7.0%	162,902	153,807	5.9%
ARPOB (₹ /day) ^(^)	63,569	59,523	6.8%	60,588	57,488	5.4%

¹ Outpatient Volume represents New Registrations only | ² Revenue will differ from the consolidated revenues as this includes Delhi which is not consolidated under Ind AS 116 due to joint control



Metro:- Chennai ; Non Metro:- Madurai, Karur, Karaikudi, Trichy and Nellore



	Tamil Nadu Region					
	Q4FY25	Q4FY24	YoY	FY25	FY24	YoY
Operating Beds	2,068	2,029	1.9%	2,068	2,029	1.9%
Bed Occupancy Rate (%)	65%	63%		64%	63%	
Inpatient volume	37,308	37,000	0.8%	152,668	148,512	2.8%
Outpatient volume ⁽¹⁾	151,095	143,322	5.4%	610,107	580,149	5.2%
Inpatient ALOS (days)	3.23	3.17	1.9%	3.15	3.15	-0.1%
Total Net Revenue (₹ mio)	9,405	8,796	6.9%	37,231	34,184	8.9%
Avg revenue per In Patient	197,159	182,198	8.2%	187,628	175,030	7.2%
ARPOB (₹ /day) ^(^)	78,133	75,050	4.1%	77,509	73,064	6.1%

^ARPOB is net of fees paid to fee for service doctors which is netted off in the reported revenues

FY25

Metro

Operating Beds	 1,383
Occupancy	 65%
ARPOB ^	 93,007

Non Metro

Operating Beds	 685
Occupancy	 61%
ARPOB ^	 44,039

Expansion Plan

Location	Nature	Total Beds	Census Beds
OMR, Chennai	Greenfield	600	500

¹ Outpatient Volume represents New Registrations only.

AP, Telangana Region

Metro:- Hyderabad; Non Metro:- Karimnagar, Vizag and Kakinada



	AP, Telangana Region					
	Q4FY25	Q4FY24	YoY	FY25	FY24	YoY
Operating Beds	1,240	1,270	-2.4%	1,240	1,270	-2.4%
Bed Occupancy Rate (%)	64%	56%		67%	57%	
Inpatient volume	20,847	18,933	10.1%	86,689	77,036	12.5%
Outpatient volume ⁽¹⁾	89,063	56,566	57.4%	318,135	220,817	44.1%
Inpatient ALOS (days)	3.40	3.42	-0.5%	3.48	3.43	1.6%
Total Net Revenue (₹ mio)	4,652	3,924	18.5%	18,304	15,246	20.1%
Avg revenue per In Patient	188,698	171,995	9.7%	177,356	164,509	7.8%
ARPOB (₹ /day) ^(^)	65,572	60,574	8.3%	60,610	57,708	5.0%

^ARPOB is net of fees paid to fee for service doctors which is netted off in the reported revenues

FY25

Metro

Operating
Beds

759

Occupancy

69%

ARPOB ^

70,547

Non Metro

Operating
Beds

481

Occupancy

64%

ARPOB ^

43,647

Expansion Plan

Location	Nature	Total Beds	Census Beds
Gachibowli, Hyderabad	Greenfield - Asset Light	375	300
Jubilee Hills (Expansion)	Brownfield	80	70
Secunderabad (Expansion)	Brownfield	80	70
Total		535	440

¹ Outpatient Volume represents New Registrations only.



	Karnataka Region					
	Q4FY25	Q4FY24	YoY	FY25	FY24	YoY
Operating Beds	772	748	3.2%	772	748	3.2%
Bed Occupancy Rate (%)	70%	68%		74%	67%	
Inpatient volume	16,278	16,019	1.6%	69,499	64,241	8.2%
Outpatient volume ⁽¹⁾	68,475	55,779	22.8%	272,794	210,037	29.9%
Inpatient ALOS (days)	2.97	2.91	2.2%	2.99	2.85	4.9%
Total Net Revenue (₹ mio)	3,416	2,980	14.6%	13,287	11,423	16.3%
Avg revenue per In Patient	175,796	156,722	12.2%	160,602	149,697	7.3%
ARPOB (₹ /day) ^(^)	70,598	63,952	10.4%	63,985	62,422	2.5%

^ARPOB is net of fees paid to fee for service doctors which is netted off in the reported revenues

FY25

Metro

Operating Beds

559

Occupancy

75%

ARPOB ^

70,758

Non Metro

Operating Beds

213

Occupancy

71%

ARPOB ^

45,260

Expansion Plan

Location	Nature	Total Beds	Census Beds
Malleswaram & Mysore Expansion	Brownfield	140	125
Sarjapur-1	Acquisition - Leased facility	200	160
Sarjapur-2	Greenfield	500	400
Total		840	685

¹ Outpatient Volume represents New Registrations only



	Eastern Region					
	Q4FY25	Q4FY24	YoY	FY25	FY24	YoY
Operating Beds	1,867	1,820	2.6%	1,867	1,820	2.6%
Bed Occupancy Rate (%)	73%	74%		75%	74%	
Inpatient volume	32,885	31,730	3.6%	134,041	125,209	7.1%
Outpatient volume ⁽¹⁾	106,723	104,079	2.5%	451,803	412,895	9.4%
Inpatient ALOS (days)	3.74	3.86	-3.2%	3.80	3.92	-3.0%
Total Net Revenue (₹ mio)	5,962	5,546	7.5%	23,715	21,404	10.8%
Avg revenue per In Patient	146,318	138,896	5.3%	141,006	135,613	4.0%
ARPOB (₹ /day) ^(^)	48,462	45,245	7.1%	46,572	43,661	6.7%

[^]ARPOB is net of fees paid to fee for service doctors which is netted off in the reported revenues

FY25

Metro

Operating
Beds

736

Occupancy

81%

ARPOB ^

61,225

Non Metro

Operating
Beds

1,131

Occupancy


70%

ARPOB ^

35,580

Expansion Plan

Location	Nature	Total Beds	Census Beds
Sonarpur, Kolkata	Hospital Asset Acquisition	270	220



	Western Region					
	Q4FY25	Q4FY24	YoY	FY25	FY24	YoY
Operating Beds	876	861	1.7%	876	861	1.7%
Bed Occupancy Rate (%)	56%	57%		58%	55%	
Inpatient volume	13,508	12,698	6.4%	53,703	50,221	6.9%
Outpatient volume ⁽¹⁾	54,305	52,807	2.8%	225,262	211,618	6.4%
Inpatient ALOS (days)	3.27	3.52	-7.1%	3.48	3.47	0.3%
Total Net Revenue (₹ mio)	2,478	2,173	14.0%	9,448	8,326	13.5%
Avg revenue per In Patient	153,270	139,023	10.2%	145,193	133,493	8.8%
ARPOB (₹ /day) ^(^)	56,053	48,575	15.4%	50,581	47,827	5.8%

^ARPOB is net of fees paid to fee for service doctors which is netted off in the reported revenues

FY25

Metro

Operating Beds	392
Occupancy	64%
ARPOB ^	58,293

Non Metro


Operating Beds	484
Occupancy	54%
ARPOB ^	43,097

Expansion Plan

Location	Nature	Total Beds	Census Beds
Royal Mudhol, Pune	Hospital Asset Acquisition	400	325
Worli, Mumbai	Greenfield	575	500
Total		975	825

¹ Outpatient Volume represents New Registrations only.

Metro:- Delhi; Non Metro:- Lucknow and Indore



	Northern Region					
	Q4FY25	Q4FY24	YoY	FY25	FY24	YoY
Operating Beds	1,202	1,217	-1.2%	1,202	1,217	-1.2%
Bed Occupancy Rate (%)	70%	66%		73%	68%	
Inpatient volume	25,608	24,192	5.9%	107,650	98,827	8.9%
Outpatient volume ⁽¹⁾	90,156	67,266	34.0%	354,289	287,180	23.4%
Inpatient ALOS (days)	2.97	3.01	-1.5%	2.97	3.05	-2.6%
Total Net Revenue (₹ mio)	4,876	4,477	8.9%	19,834	17,766	11.6%
Avg revenue per In Patient	162,100	157,743	2.8%	156,718	152,556	2.7%
ARPOB (₹ /day) ^(^)	64,191	61,447	4.5%	62,097	59,013	5.2%

[^]ARPOB is net of fees paid to fee for service doctors which is netted off in the reported revenues

FY25

Metro

Operating
Beds



749

Occupancy



73%

ARPOB ^



67,309

Non Metro

Operating
Beds



453

Occupancy



72%

ARPOB ^




53,408

Expansion Plan

Location	Nature	Total Beds	Census Beds
Gurgaon, NCR	Hospital Asset Acquisition	510	420
Varanasi, U.P	Greenfield	400	300
Lucknow (Expansion), U.P	Brownfield	200	160
Defence Colony, Delhi	Brownfield	42	27
Total		1152	907

¹ Outpatient Volume represents New Registrations only.




Healthcare Services: Expansion Plan



Location	Nature	Total Beds	Census Beds	Project Cost (in Crs)	Balance Project Cost (in Crs)
Expected commissioning : FY26					
Royal Mudhol, Pune	Hospital Asset Acquisition	400	325	₹ 630	₹ 260
Sonarpur, Kolkata	Hospital Asset Acquisition	270	220	₹ 310	₹ 130
Gachibowli, Hyderabad	Greenfield - Asset Light	375	300	₹ 515	₹ 390
Gurgaon, NCR	Hospital Asset Acquisition	510	420	₹ 1,190	₹ 585
Defence Colony, Delhi	Brownfield	42	27	₹ 65	₹ 25
Sarjapur-1	Acquisition - Leased facility	200	160	₹ 285	₹ 278
Malleswaram & Mysore Expansion	Brownfield	140	125	₹ 170	₹ 165
		1,937	1,577	₹ 3,165	₹ 1,833
Expected commissioning : In next 3 - 4years					
OMR, Chennai	Greenfield	600	500	₹ 945	₹ 690
Varanasi, U.P	Greenfield	400	300	₹ 640	₹ 540
Worli, Mumbai	Greenfield	575	500	₹ 1,315	₹ 1,215
Lucknow (Expansion), U.P	Brownfield	200	160	₹ 320	₹ 235
Sarjapur-2	Greenfield	500	400	₹ 944	₹ 734
Jubilee Hills (Expansion)	Brownfield	80	70	₹ 220	₹ 220
Secunderabad (Expansion)	Brownfield	80	70	₹ 545	₹ 545
		2,435	2,000	₹ 4,929	₹ 4,179
Total		4,372	3,577	₹ 8,094	₹ 6,012

Continue to evaluate bolt-on acquisitions in select Tier -1 cities & Metros



Diagnostics & Retail Health

Apollo Health & Lifestyle Ltd

Primary Care



- ▶ Core revenues of Primary Care grew by ~16% YoY in FY25, as a result of revamped health check plans and strengthening of corporate outreach
- ▶ Improvement in margin profile primarily due to optimization of fixed costs
- ▶ Preventive Health-checks volume grew by ~17% YoY in FY25
- ▶ Plan to expand service offerings in Core Clinics – weight loss, joint preservation etc.
- ▶ Net addition of 10 Centres in Dialysis in FY25

Diagnostics



- ▶ Wellness segment volume grew by ~18% YoY in FY25 & accounted ~19% of Diagnostics revenue (vs ~16% in FY24)
- ▶ Continuous improvement in EBITDA margin over the past 2 years (~10% in FY25 vs ~6% in FY23)
- ▶ 110 tests started inhouse in FY25. Added IC-PMS based heavy metal testing, culture identification, various cytogenetics related testing, microarray analysis to the portfolio in Q4 FY25
- ▶ Existing business model of Franchisee modified into a more profitable model

Specialty Care



- ▶ Spectra: ~19% YoY revenue growth in FY25 driven by operationalization of renovated centers. Renovated Jaipur centre commissioned recently and is expected to increase revenue contribution in FY26
- ▶ Cradle: ~12% YoY revenue growth in FY25. 1 New centre operationalized in Bangalore
- ▶ Fertility: ~15% YoY revenue growth in FY25 driven by expanding patient base

		Primary Care	Diagnostics	Specialty Care	Corporate / Intra Group	AHLL
Q4FY25	Revenue	1,150	1,278	1,708	-197	3,940
	EBITDA	268	116	197	-109	472
	margin (%)	23.3%	9.1%	11.5%		12.0%
	EBIT	194	57	-16	-117	118
	PAT	145	43	-309	59	-62
Q4FY24	Revenue	1,026	1,169	1,558	-207	3,547
	EBITDA	264	168	82	-157	357
	margin (%)	25.7%	14.3%	5.3%		10.1%
	EBIT	196	130	-98	-160	68
	PAT	175	120	-244	-177	-127
Growth						
	Revenue	12%	9%	10%	-	11%
	EBITDA	2%	-31%	141%	-	32%

- ✓ AHLL revenue & EBITDA grew by 11% & 32% YoY in Q4'FY25 respectively; primarily driven by network maturity across key segments
- ✓ Primary care revenue grew by 12% YoY in Q4'FY25 due to strengthening of corporate outreach
- ✓ Specialty care revenue grew by 10% YoY in Q4'FY25 due to expanding patient base

Network	Primary Clinics	Sugar Clinics	Dental Clinics	Dialysis	Diagnostics	Spectra ¹	Birthing Centers ^{1*}	Total
	267	76	219	146	2,212	23	35	2,978
Footfalls / Day	2,661	502	233	2,359	14,898	82	104	23,323
Gross ARPP	2,379	3,249	6,503	1,648	822	104,301	84,167	1,961



		Primary Care	Diagnostics	Specialty Care	Corporate / Intra Group	AHLL
FY25	Revenue	4,277	5,000	6,965	-706	15,535
	EBITDA	844	523	773	-602	1,538
	margin (%)	19.7%	10.5%	11.1%		9.9%
	EBIT	557	342	8	-607	300
	PAT	435	309	-515	-622	-393
FY24	Revenue	3,743	4,605	6,048	-743	13,653
	EBITDA	682	504	633	-653	1,166
	margin (%)	18.2%	10.9%	10.5%		8.5%
	EBIT	414	367	-131	-665	-15
	PAT	290	334	-619	-744	-739
Growth						
	Revenue	14%	9%	15%	-	14%
	EBITDA	24%	4%	22%	-	32%


- ✓ AHLL revenue & EBITDA grew by 14% & 32% YoY in FY25 respectively; primarily driven by network maturity across key segments
- ✓ Primary care revenue and EBITDA grew by 14% and 24% YoY in FY25 respectively due to revamped health check plans & optimization of fixed cost
- ✓ Specialty care revenue grew by 15% YoY in FY25 due to operationalization of renovated centres

Network	Primary Clinics	Sugar Clinics	Dental Clinics	Dialysis	Diagnostics	Spectra ¹	Birthing Centers ^{1*}	Total
	267	76	219	146	2,212	23	35	2,978
Footfalls / Day	2,575	501	224	2,285	14,805	85	173	23,049
Gross ARPP	2,291	3,212	6,903	1,628	814	102,206	82,150	1,950


Diagnostics : Key Parameters



Gross Revenue (INR Mn)



EBITDA (INR Mn)¹




Operational footprint
(as of March 31, 2025)


~330+
Cities
presence

104
Labs

Avg. Footfalls per day & Avg. gross realization per patient (INR)*



Network Growth – Collection Centers[#]




2,100+
Collection Centres

3,000+
Pick-up Points
(PUPs)

1. EBITDA post IND AS 116;

* Footfalls and ARPV for diagnostics represent outpatient / external business

[#] Rationalized the commission structure for collection centers, resulting in reduction of centers in Q2 FY25 & Q4FY25.



Digital Health & Pharmacy Distribution **Apollo HealthCo**

India's Largest Omni-Channel Healthcare Platform



Apollo 247 Digital Platform



~40 Mn+ Registrations




~11,999 Doctors

Daily Active Users 8.2 Lakh


Daily Consultations 15,400+

Daily Medicine Orders 59,000+

Daily Sample Collections ~2,400+



Apollo Pharmacy Platform



6,626 Stores

~16.2%

Added - FY

607

Closed - FY

11

Net

596

Omni Private label / generics mix - FY25

Virtual Doctor Consultation

Online Booking : Hospitals & Diagnostics

Online Medicine delivery

Insurance



Patient e-health records

Condition management

Apollo HealthCo Financials Q4FY25

₹ Mio		Offline Pharmacy Distribution	Online Pharmacy Distribution & Apollo 247	Total HealthCo
Q4FY25	Total Revenues	20,844	2,919	23,763
	EBITDA (Pre 24 7 Cost)	1,616	350	1,966
	margin (%)	7.8%	12.0%	8.3%
	24/7 Operating Cost		-1,147	-1,147
	ESOP(Non Cash expense)		-455	-455
	EBITDA	1,616	-1,253	363
	margin (%)	7.8%	-	1.5%
	EBIT			230
	PBT			88
	PAT (Reported)			88
Q4FY24	Total Revenues	17,880	2,387	20,267
	EBITDA (Pre 24 7 Cost)	1,336	289	1,625
	margin (%)	7.5%	12.1%	8.0%
	24/7 Operating Cost		-1,402	-1,402
	ESOP(Non Cash expense)		-106	-106
	EBITDA	1,336	-1,219	117
	margin (%)	7.5%	-	0.6%
	EBIT			-6
	PBT			-179
	PAT (Reported)			-177
Revenue		17%	22%	17%
EBITDA (Pre 24 7 Cost)		21%	21%	21%

* Excluding 24|7 operating Cost and ESOP Non-Cash Charge



*Cash loss/profit is EBITDA post Ind As excluding ESOP expense

Healthco (Q4' FY25 vs Q4' FY24):

- 17% growth in revenue in Q4' FY25 vs Q4' FY24
- PAT positive in Q4'FY25** (Rs. 88 Mn) vs **loss** of Rs. 177 Mn in Q4'FY24 on account of growth in operational revenue and optimization of 247 operating cost, lower finance charges partially getting offset by increase in non cash charge item (ESOP)

Omnichannel Healthcare Division:

- Omnichannel Pharmacy (AHL+ APL) Business revenue of Rs 30,401 Mn in Q4' FY25 compared to a revenue of Rs. 25,876 Mn in Q4' FY24 (growth of 17.5%).
- Apollo Telehealth (under AHEL) Revenues of Rs.175 Mn in Q4FY25.

Digital Operational Metrics :

- Platform GMV : Rs 7,954 Mn in Q4' FY25, growth of 11% over Q4' FY24
- New customer acquisition channel started to gain traction (launch of 19 mins & Omni Acquisition)
- Continuous Improvement in quantitative parameters in Q4' FY25 vs Q4' FY24:
 - 25% YoY growth in Online Pharma Transactions.
 - DAU Mar exit shows YoY growth of 45%

Offline Segment

- 12.6% YoY growth in offline transactions (8.0 cr Vs 7.1 cr year back).
- Serving ~8.9 lac offline customers per day

₹ Mio		Offline Pharmacy Distribution	Online Pharmacy Distribution & Apollo 247	Total HealthCo
FY25	Total Revenues	80,143	10,787	90,930
	EBITDA (Pre 24 7 Cost)	6,124	1,409	7,533
	margin (%)	7.6%	13.1%	8.3%
	24/7 Operating Cost		-4,781	-4,781
	ESOP(Non Cash expense)		-1,076	-1,076
	EBITDA	6,124	-4,449	1,676
	margin (%)	7.6%	-	1.8%
	EBIT			1,127
	PBT			469
	PAT (Reported)			469
FY24	Total Revenues	69,268	9,001	78,269
	EBITDA (Pre 24 7 Cost)	5,230	1,029	6,260
	margin (%)	7.6%	11.4%	8.0%
	24/7 Operating Cost		-6,186	-6,186
	ESOP(Non Cash expense)		-891	-891
	EBITDA	5,230	-6,047	-817
	margin (%)	7.6%	-	-
	EBIT			-1,309
	PBT			-1,956
	PAT (Reported)			-1,957
Revenue		16%	20%	16%
EBITDA (Pre 24 7 Cost)		17%	37%	20%

* Excluding 24|7 operating Cost and ESOP Non-Cash Charge



Healthco (FY 25 vs FY24);

- 16% growth in revenue in FY25 vs FY24
- **PAT positive in FY25** Rs. 469 Mn **vs loss** of (Rs.1,957 Mn) in FY24 on account of optimization of cost and growth in operational revenue.



Omnichannel Healthcare Division

Omnichannel Pharmacy Business (AHL + APL) revenue of Rs 1,15,221 Mn in FY25 compared to a revenue of Rs. 98,945 Mn in FY24 (growth of 16.4%).

Apollo Telehealth (under AHEL) Revenue of Rs. 701 Mn in FY25 (growth of 32%) compared to FY24




Digital Operational Metrics :

Platform GMV : Rs 30,073 Mn in FY25, growth of 8% over FY24



Offline Segment

- 12.6% YoY growth in offline transactions (30.8 cr Vs 27.4 cr year back).



- Apollo Healthco Limited (“AHL”) raised **equity capital of INR 2,475 Crs (USD 300 Mn)** from Advent International (“Advent”)¹, one of the largest global private equity investors with an AUM of over USD 94 Bn. Tranche 1 of INR 1,732 crs and Tranch 2 of INR 743 crs completed².
- **Integration of Keimed Private Limited (“Keimed”) with AHL** proposed in a phased manner.
- Merger with Keimed estimated to be EPS accretive from Year 1.
- To create **India’s leading integrated pharmacy distribution business complemented by fast growing omni-channel digital health business.**
- Keimed is the market leader in wholesale pharma distribution with 2x the scale of nearest competitor and industry leading operating metrics. AHL to utilize Keimed’s vast network of 70,000+ stores to accelerate its INR 1,500+ Crs (USD 0.18 Bn) private label portfolio.
- **Merged entity will have an industry defining business model with Pan India presence.**
- **Target consolidated Year 3 revenues of ~INR 25,000 Crs³ (USD 3.03 Bn) with operating margins* of 7-8%.**

¹ Rasmeli Limited, an affiliate of Advent International

² The investment received from Advent International, in Apollo Healthco Ltd in the form of Compulsorily Convertible Preference shares (CCPs) is recorded as a Financial liability under IND AS 32 as the CCPs though will be fully Equity settled, could have some variability pursuant to the adjustments in accordance with the transaction agreements. Management does not expect any material variability from the 12.125% effective share holding of Advent in the Combined entity (Apollo Healthco Ltd including Keimed Private Limited).


³ On a Proforma Basis

*Post 24/7 Operating Cost

Synergetic Benefit of the Keimed Merger



Becoming India's Leading Healthcare Provider



... with Improving Cost Efficiency and Margins


Supply chain efficiencies, together with above permanently changes AHL's margins, allowing for a growth story that outpaces our status quo.




EBITDA expansion in both AHL and Keimed over the next 2 years



Integrated Business Model Driving Revenue Growth...








Proposed Transaction Structure and Steps (2/2)



1 Internal restructuring of Keimed Group; Post restructuring all JV's to be 100% owned by Keimed

2 Keimed is proposed to be merged with AHL through a scheme of arrangement with NCLT approval

** Includes economic interest of AHEL holding of 49% in FHPL; AHEL effective economic interest through FHPL post merger process is 2.5% ; # Includes 3.6% of Keimed minority partners ; + may be adjusted upwards pursuant to the adjustments in accordance with transaction agreements



Combined Financials Metrix| Snapshot FY25




(₹ mio)




	FY24	Offline Pharma Distribution	Online Pharma Distribution+247	Total Healthco	Keimed	Combined FY25	Combined Q4'FY25
Revenue	137,701	80,143	10,787	90,930	130,062	163,772	42,455
EBITDA,Pre INDAS	9,614	5,908	1,373	7,282	3,898	11,180	2,801
EBITDA %	7.0%	7.4%	12.7%	8.0%	3.0%	6.8%	6.6%
24/7 Operating cost	-6,186	-	-4,781	-4,781	-	-4,781	-1,147
ESOP Non Cash charge	-891	-	-1,076	-1,076	-	-1076	-455
EBITDA, Pre IndAS	2,533	5,908	-4,484	1,424	3,898	5,322	1,198
EBITDA %	1.8%	7.4%	N.M.	1.6%	3.0%	3.2%	2.8%
Excluding Digital	6.7%					6.4%	6.2%

At 24% annual CAGR on FY25, we expect to achieve INR 250 bn of revenue in FY27 with 7-8% EBITDA



Annexure



Basis of Consolidation



AHEL Standalone Hospitals (100% Ownership)	Location
Chennai Main	Chennai
ACI - Chennai	Chennai
Tondiarpet - Chennai	Chennai
FirstMed - Chennai	Chennai
Apollo Children's Hospital	Chennai
Apollo Specialty, Vanagaram	Chennai
ASH Perungudi	Chennai
Women & Child, Shafee Mohammed Road	Chennai
Apollo Proton & Cancer care	Chennai
Madurai	Madurai
Karur	Karur
Karaikudi	Karaikudi
Trichy	Trichy
Nellore	Nellore
Hyderabad	Hyderabad
Bilaspur	Bilaspur
Rourkela	Odisha
Mysore	Mysore
Vizag (old & new)	Vizag
Karim Nagar	Karim Nagar
Bhubaneswar	Bhubaneswar
Jayanagar	Bangalore
Nashik	Nashik
Malleswaram	Bangalore
Navi Mumbai	Mumbai

Subsidiaries	Location	Description	AHEL Ownership
Material Subs			
Apollo Health Co limited	India	Digital Omni-Channel Healthcare services Platform	100.00%
Apollo Health and Lifestyle Ltd.	India	Clinics, Diagnostics and Daycare	68.84%
Apollo Multispeciality Hospitals Ltd.	Kolkata	Hospital	100.00%
Apollo Medics	Lucknow	Hospital	51.00%
Imperial Hospital and Research Centre Ltd.	Bangalore	Hospital	90.00%
Apollo Hospitals International Ltd.	Ahmedabad	Hospital	50.00%
Assam Hospitals Ltd	Assam	Hospital	70.87%
Apollo Rajshree Hospital	Indore	Hospital	54.63%
Samudra Healthcare Enterprises Ltd.	Kakinada	Hospital	100.00%
Other Subs			
Apollo Hospitals (UK) Ltd	UK	UK Hold Co	100.00%
AB Medical Centres Limited	Chennai	Infrastructure	100.00%
Total Health	India	CSR	100.00%
Apollo Hospitals Singapore.PTE Limited	Singapore	Singapore Hold Co	100.00%
Future Parking Pvt Ltd	Chennai	Infrastructure	100.00%
Apollo Home Health care Ltd	India	Paramedical Services	74.00%
Pinakini Hospitals Ltd.	Nellore	Hospital	80.87%
Sapient Biosciences Pvt Ltd	Hyderabad	Biobanking tissues	70.00%
Apollo Lavasa Health Corporation Ltd	Maharashtra	Hospital	51.00%
Apollo Hospitals North Limited	Gurgaon	Hospital	100.00%
Apollo Hospitals Worli LLP	Mumbai	Hospital	90.10%
Health Axis	Hyderabad	Healthcare Technologies and Remote healthcare	69.99%
Kerala First Health Services Private Limited	Kerala	Hospital	60.00%
Associates			
Indraprastha Medical Corporation Ltd.	Delhi, Noida	Hospital	22.03%
Family Health Plan Ltd.	India	TPA, Health Insurance	49.00%
ApoKos Rehab Pvt Ltd	Hyderabad	Rehab Centre	50.00%
Stemcyte India Therapeutics Pvt Ltd	India	Stemcell Banking	37.75%
Apollo Gleneagles PET-CT Pvt Ltd	Hyderabad	Diagnostics	50.00%

AHEL Standalone (post IND AS 116)



Balance sheet

Right of use Asset as of 31 st Dec, 2024	13,285
Lease liabilities as of 31 st Dec, 2024	13,064
Equity (Transaction impact as on Apr 01, 2019 - Net of Tax)	2,109



Profit & Loss

Revenue	
Other expenses (Lease rent)	1,102
EBITDA	1,102
Amortisation	698
EBIT	403
Finance charge	708
PBT	305

AHEL Consolidated (post IND AS 116)



Balance sheet

Right of use Asset as of 31 st Dec, 2024	24,653
Lease liabilities as of 31 st Dec, 2024	25,891
Equity (Transaction impact as on Apr 01, 2019 - Net of Tax)	3,052



Profit & Loss

Revenue	
Other expenses (Lease rent)	2,537
EBITDA	2,537
Amortisation	1,675
EBIT	863
Finance charge	1,533
PBT	670

Thank you !!